Generali Investments Towarzystwo Funduszy Inwestycyjnych Crispr Therapeutics Ag Transaction History
Generali Investments Towarzystwo Funduszy Inwestycyjnych
- $172 Billion
- Q4 2024
A detailed history of Generali Investments Towarzystwo Funduszy Inwestycyjnych transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Generali Investments Towarzystwo Funduszy Inwestycyjnych holds 19,000 shares of CRSP stock, worth $802,180. This represents 0.43% of its overall portfolio holdings.
Number of Shares
19,000
Previous 15,000
26.67%
Holding current value
$802,180
Previous $705 Million
6.12%
% of portfolio
0.43%
Previous 0.45%
Shares
5 transactions
Others Institutions Holding CRSP
# of Institutions
485Shares Held
58.9MCall Options Held
1.09MPut Options Held
1.9M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl8.97MShares$379 Million3.09% of portfolio
-
Capital International Investors Los Angeles, CA7.93MShares$335 Million0.07% of portfolio
-
State Street Corp Boston, MA2.99MShares$126 Million0.01% of portfolio
-
Nikko Asset Management Americas, Inc.2.97MShares$125 Million1.61% of portfolio
-
Black Rock Inc. New York, NY2.78MShares$117 Million0.0% of portfolio
About CRISPR Therapeutics AG
- Ticker CRSP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 78,009,296
- Market Cap $3.29B
- Description
- CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....